Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/16228
|
| Title: | Registry of genetic alterations of Taiwan non-small cell lung cancer by comprehensive next-generation sequencing: A real-world cohort study-Taiwan cooperative oncology group T1521 |
| Authors: | Liao, BC;Chiang, NJ;Chang, GC;Su, WC;Luo, YH;Chong, IW;Yang, TY;Lai, CL;Hsia, TC;Ho, CL;Lee, KY;Hsiao, CF;Ku, FC;Fang, WT;Chih-Hsin Yang, J |
| Contributors: | National Institute of Cancer Research;Institute of Population Health Sciences |
| Abstract: | PURPOSE: Tissue-based next-generation sequencing (NGS) analysis is highly recommended for patients with advanced/metastatic non-small cell lung cancer (NSCLC). We investigated a specific patient population with NSCLC that required tissue-based NGS analysis. MATERIALS AND METHODS: We enrolled 500 patients with advanced/metastatic (1) epidermal growth factor receptor (EGFR) mutations or anaplastic large-cell lymphoma kinase (ALK) rearrangement-positive NSCLC who had failed at minimum one line of tyrosine kinase inhibitor (TKI) therapy, (2) EGFR-/ALK-negative nonsquamous, and (3) non- or light-smoker patients with squamous NSCLC who were treatment-naïve or had failed at maximum two lines of systemic treatment. These patients were divided into five cohorts. Comprehensive tissue-based NGS testing (ACTOnco+) was conducted. RESULTS: Cohort 1: EGFR TKI-pretreated EGFR-mutated population (50.0%, n = 250), cohort 2: ALK inhibitor-pretreated ALK-positive population (1.6%, n = 8), cohort 3: treatment-naïve EGFR-/ALK-negative population (28.2%, n = 141), cohort 4: pretreated EGFR-/ALK-negative population (16.8%, n = 84), and cohort 5: squamous cell carcinoma (3.4%, n = 17). In cohort 1, 11.2% (28/250) of the patients had MET amplification, 32.4% (81/250) had been treated with osimertinib, and EGFR C797S was detected in 6.2% (5/81) of these patients. In cohort 2, resistance ALK mutation was detected in 37.5% (3/8) of the patients. In cohorts 3 and 4, targetable genetic alterations, including EGFR mutation (13.3%), ERBB2 mutation (9.3%), MET exon 14 skipping (5.3%), KRAS G12C mutation (4.4%), ROS1 fusion (2.7%), RET fusion (1.8%), and BRAF V600E mutation (1.3%), were detected. In cohort 5, MET exon 14 skipping was detected in 29.4% (5/17) of the patients. CONCLUSION: This multicenter registration study investigated tissue-based NGS for a specific patient population with NSCLC in Taiwan. |
| Date: | 2024-09-30 |
| Relation: | JCO Global Oncology. 2024 Sep 30;10:Article number e2400125. |
| Link to: | http://dx.doi.org/10.1200/go.24.00125 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85205447106 |
| Appears in Collections: | [姜乃榕] 期刊論文
[蕭金福] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB39348626.pdf | | 546Kb | Adobe PDF | 22 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
